U.S. Transportation Stock News

Generac Holdings Inc. reported past first-quarter 2026 results with sales of US$1,059.37 million and net income of US$73.25 million, alongside higher earnings per share than a year earlier. Alongside these results, management slightly raised its full-year 2026 sales growth outlook while maintaining its expected net income margin range of 8.0% to 9.0%, reinforcing confidence in operational progress. With full-year sales growth guidance raised to the mid-to-high teens, we’ll now examine how...

Host Hotels & Resorts (HST) is in focus after reporting first quarter 2026 results that exceeded profitability expectations, lifted its full year comparable hotel RevPAR guidance, and paired asset sale gains with a special dividend announcement. See our latest analysis for Host Hotels & Resorts. The share price has reacted positively to the first quarter update, with a 1 day share price return of 2.77% and a 7 day share price return of 6.76%. The 1 year total shareholder return of 49.75% and...

ArriVent BioPharma (AVBP) drew fresh attention after announcing FDA clearance of its investigational new drug application for ARR-002, a first-in-class dual-target antibody-drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharma. Despite a recent dip, with a 1 day share price return down 2.60% and 7 day share price return down 7.20%, ArriVent’s 30 day and year to date share price returns of 14.53% and 38.70%, alongside a 1 year total shareholder...

Tecnoglass Q1 earnings and reaffirmed guidance Tecnoglass (TGLS) reported first quarter 2026 revenue of US$249.01 million compared with US$222.29 million a year earlier, while net income declined to US$31.89 million and earnings per share moved to US$0.71 from US$0.90. Alongside these mixed results, the company reaffirmed full year 2026 revenue guidance of US$1.06b to US$1.13b. This gives investors updated context for assessing how the current trading price lines up with management’s...

USA TODAY (TDAY) stock is in focus after the company returned to profitability in the first quarter of 2026, posting positive net income and reaffirming full year earnings guidance despite lower revenue. See our latest analysis for USA TODAY. The earnings return to profit and reaffirmed 2026 guidance have arrived alongside strong momentum, with a 90 day share price return of 26.96% and a 1 year total shareholder return of 105.66%, suggesting sentiment has strengthened around the earnings...

Rambus recently launched its PCIe 7.0 Switch IP with Time Division Multiplexing, expanding its interconnect portfolio to support bandwidth-intensive AI, cloud, and high-performance computing systems while aiming to improve link utilization and reduce system complexity for large-scale distributed architectures. This new switch IP strengthens Rambus’ position in high-speed interface IP by targeting emerging disaggregated and pooled compute designs that require deterministic, low-latency data...

If you are wondering whether Sonos stock still offers value after a strong run or a rough patch, this article breaks down what the current price might be telling you. Over the past year, the stock has returned 44.4%, compared with a 16.1% gain over the last 30 days, while year to date it is down 13.9% and the 5-year return sits at a 55.5% loss. Recent headlines around Sonos have focused on its role in the consumer audio market and how sentiment has shifted around the stock. These stories...

What Essent Group’s latest quarter means for investors Essent Group (ESNT) just posted first quarter results that topped analyst earnings and revenue expectations, alongside an affirmed US$0.35 quarterly dividend and updates on its growing property & casualty reinsurance platform. See our latest analysis for Essent Group. The earnings beat and reaffirmed dividend have arrived alongside a recent pick up in momentum, with a 1 day share price return of 2.52% and 7 day share price return of...

In early May 2026, Caris Life Sciences reported first-quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss improving to US$0.51 million, while also securing MolDX approval for its Caris ChromoSeq whole genome assay and launching the AI-driven Caris MI Clarity breast cancer prognostic test. Together, these developments highlight Caris’ efforts to broaden its precision oncology portfolio across hematologic malignancies and early-stage breast cancer, while...

Valero Energy (VLO) has just paired a regular quarterly dividend of $1.20 per share with a sharp swing back to profitability in the first quarter, giving investors fresh numbers to reassess the stock. See our latest analysis for Valero Energy. The recent quarterly profit and steady dividend come against a share price of $236.35, with a 90 day share price return of 16.61% and a year to date share price return of 42.97%. The 1 year total shareholder return of 99.87% suggests strong momentum has...

Mondelez International recently reported first-quarter 2026 results, with sales rising to US$10.08 billion and net income increasing to US$560 million, alongside higher basic and diluted earnings per share of US$0.44 from continuing operations. In addition, the company’s chief global inclusion and learning officer is scheduled to speak at the ISG Future Workplace Summit in New York, highlighting how its focus on workforce development and inclusion sits alongside its improving financial...

In the past week, BeOne Medicines AG reported first-quarter 2026 results with revenue of US$1,513.44 million and net income of US$227.36 million, raised its full-year 2026 revenue and GAAP operating income guidance, and filed an omnibus shelf registration of up to about US$9.12 billion in various securities. The company also received FDA Priority Review and Breakthrough Therapy Designation for its TEVIMBRA and ZIIHERA combination in HER2-positive gastroesophageal adenocarcinoma, supported by...

Nuvation Bio (NUVB) has drawn fresh attention after reporting first quarter revenue of US$83.23 million and a profit of US$5.4 million, alongside new FDA and guideline milestones for its oncology drug IBTROZI. See our latest analysis for Nuvation Bio. The stock has been volatile, with a 1-day share price return of a 4.56% decline following a strong 7-day share price return of 8.09%. The year-to-date share price return of a 43.94% decline contrasts with a very large 1-year total shareholder...

SL Green Realty (SLG) is back in focus after its One Madison Avenue project received the 2026 Urban Land Institute Award for Excellence in Development and reached 100% leasing, alongside flagship peer asset One Vanderbilt. See our latest analysis for SL Green Realty. The award recognition comes as momentum in SL Green Realty’s stock has picked up, with a 6.77% 7 day share price return and a 20.55% 30 day share price return. The 1 year total shareholder return is a 14.13% loss, while the 3...

SPX Technologies (SPXC) drew investor attention after first quarter sales reached US$566.8 million with net income of US$59.9 million, alongside higher full year 2026 revenue guidance in the range of US$2.575 billion to US$2.645 billion. See our latest analysis for SPX Technologies. The latest earnings update and raised 2026 revenue guidance came as the share price has been relatively flat year to date, with a 0.99% share price return. Total shareholder return over the past year is 37.43%,...

In early May 2026, BorgWarner reported first‑quarter 2026 sales of US$3,533 million and net income of US$242 million, while maintaining full‑year guidance that targets net sales of US$14.00–US$14.30 billion and a U.S. GAAP operating margin of 9.7%–9.9%. A wave of recent program wins in electrified and emissions-focused technologies, spanning Asian eMotor awards and a Euro 7 commercial vehicle platform, suggests BorgWarner is deepening its role in next‑generation propulsion across both...

Recent performance and business snapshot Lantheus Holdings (LNTH) has drawn attention after a stretch of strong share price performance, with the stock up over the past week, month and past 3 months, while also showing a double digit 1 year total return. The company develops diagnostic and therapeutic products used in the detection and treatment of heart disease, cancer and other conditions, reporting revenue of US$1,546.178 million and net income of US$279.031 million from its portfolio of...

Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance. See our latest analysis for Arcutis Biotherapeutics. The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has...

Vaxcyte (PCVX) is back in focus after the company reported a first quarter net loss of US$320.62 million, along with updates on its advancing VAX-31 vaccine trials and an upcoming study for VAX-A1. See our latest analysis for Vaxcyte. The stock has given up some ground recently, with a 1 day share price return of 9.84% decline and a 30 day share price return of 15.18% decline. However, the year to date share price return is 10.8% and the 1 year total shareholder return is 63.69%, suggesting...

Ultragenyx Pharmaceutical: Recent Move in Context Ultragenyx Pharmaceutical (RARE) has drawn fresh attention after its recent trading, with the stock closing at US$26.13. Investors are weighing this price against the company’s mixed return profile across the past year and the past 3 months. See our latest analysis for Ultragenyx Pharmaceutical. The recent move to US$26.13 comes after a 12.87% 1 month share price return and a 10.72% year to date share price return, set against a 27.38% 1 year...

Recent performance snapshot Spectrum Brands Holdings (SPB) has drawn attention after a mixed run in the stock, with a 7 day decline and a small drop in the latest session alongside positive returns over the month and past 3 months. Over longer periods, total return over the past year and past 3 years is positive, while the 5 year total return is slightly negative. This gives investors a mixed performance profile to weigh against the company’s fundamentals. See our latest analysis for Spectrum...

How BridgeBio Pharma stock has been trading BridgeBio Pharma (BBIO) has drawn investor attention after a strong 1 year total return of 93.54%. This contrasts with weaker recent trading, with the stock down 6.2% over the past month and 13.79% year to date. See our latest analysis for BridgeBio Pharma. The recent 1 day and 1 month share price declines sit against a much stronger backdrop, with a 1 year total shareholder return of 93.54% and a 3 year total shareholder return above 3x. This...

CVS Health (CVS) delivered first quarter 2026 earnings that came in ahead of expectations across all segments. This prompted higher full year earnings guidance and fresh attention on its pharmacy, insurance and technology plans. See our latest analysis for CVS Health. The 1-month share price return of 11.68% and 90-day share price return of 11.50% suggest momentum has picked up around the recent earnings beat and raised guidance. The 1-year total shareholder return of 33.46% points to a...

In April 2026, Mirion Technologies reported first-quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but swung from a small net income to a net loss of US$3.4 million, while also reaffirming its full-year 2026 earnings guidance. A key detail for investors is that Mirion’s full-year revenue growth outlook of approximately 22%–24% includes anticipated benefits from foreign exchange movements and recent acquisitions, which helps explain management’s confidence...